RecruitingPhase 1NCT06574100

Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults

Sponsor

University of Saskatchewan

Enrollment

20 participants

Start Date

Oct 26, 2024

Study Type

INTERVENTIONAL

Conditions

Pharmacokinetics

Summary

This project is aimed at understanding whether a new fast-dissolving cheek-administered cannabidiol strip will be absorbed better into the body than cannabidiol powder. The results of this study will help guide dosage formulation choices as well as dosing regimens in NFL athletes for concussion management.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cannabidiol and a drug called Cannabidiol for people with pharmacokinetics. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years to 35 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabidiol

Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.

DRUGCannabidiol

Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.